GE launches cell therapy thawing tech

By Dan Stanton contact

- Last updated on GMT

The VIA Thaw CB1000. Image: c/o GE Healthcare
The VIA Thaw CB1000. Image: c/o GE Healthcare
GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.

“Water bath thawing is the most common method for thawing cell therapies,”​ Philip Vanek, GE’s general manager of Cell Therapy Growth Strategy told Biopharma-Reporter.

“However, potential inconsistencies arise due to subjective determination of the thaw endpoint and risk of water-borne contamination, at the very point where the product is most valuable and most vulnerable.”

There is no easy way to record what is happening to a sample which makes it hard to know if procedures are all being followed identically, he continued, adding the process is labour-intensive, requiring staff to regularly complete contamination control procedures.

Therefore the firm has launched the VIA Thaw CB1000, an automated platform for the dry thawing of cryo-bags which Vanek told us overcomes these problems.

“VIA Thaw constantly monitors the sample temperature across multiple locations, records everything that happens in a comprehensive log and even takes a photo of the thawed therapy to prove it has been correctly handled.”

Furthermore, “the system requires no specialist skills to operate and delivers high recoveries of viable cells.”

Blossoming space

The personalised medicine space is just beginning to blossom, with last week’s Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel)​ breakthrough adding to a handful of cell and gene therapy products approved.

But the need for suitable GMP-compliant thawing systems has been highlighted for a number of years, and in 2014 the UK’s Cell and Gene Therapy Catapult partnered with Asymptote to develop a small benchtop thawing system which could accept different packaging options (vials and bags) and meet GMP requirements.

Asymptote is now part of GE Healthcare after it was acquired earlier this year​ and Vanek told us: The first in the VIA Thaw series automated, dry thawers now provides cell manufacturers with the ability to control and monitor the thawing of sensitive cell therapies.”

This latest offering is now commercially available in the US and Europe for research use in laboratory and clinical trial settings, and pre-launch marketing activities with cell therapy companies have had a positive response, he had.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers